This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Compugen Announces US Patent Allowance For Drug Candidate Recently Presented At 2013 American Thoracic Society Meeting

Stocks in this article: CGEN

Compugen Ltd. ( NASDAQ: CGEN) announced today that the company has received an Issue Notification from the U.S. Patent and Trademark Office for a patent application covering the company's drug candidate CGEN-25009. CGEN-25009 is intended for the treatment of idiopathic pulmonary fibrosis, a devastating disease with no current effective treatment. This novel peptide agonist of the relaxin receptor was the subject of a recent presentation by Dr. Daniel Kass, from the University of Pittsburgh (“Pitt”), at the 2013 American Thoracic Society Conference.

In his presentation, Dr. Kass, Assistant Professor of Medicine at Pitt and Assistant Director for Novel Therapeutics and Translational Research at The Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease at the University of Pittsburgh Medical Center, presented experimental data demonstrating that CGEN-25009 protects mice from bleomycin-induced pulmonary fibrosis. In this model, CGEN-25009 treatment reduced lung fibrosis as determined by collagen deposition in both preventive and therapeutic administration regimens.

As previously announced by Compugen, the Pulmonary Fibrosis Foundation provided a grant to scientists at Pitt to independently evaluate the therapeutic potential of CGEN-25009 for the treatment of idiopathic pulmonary fibrosis (IPF), a life-threatening disease affecting an estimated more than five million people worldwide.

Dr. Anat Cohen-Dayag, president and CEO of Compugen, stated, “We are very pleased with the CGEN-25009 results presented by Dr. Kass, and we hope that this therapeutic peptide candidate will eventually improve the lives of many patients.”

Dr. Cohen-Dayag added, “The new US patent, which will be issued on July 23, 2013 as US Patent No. 8,492,329, as well as previous patents granted or allowed for CGEN-25009 in the European Union and Australia, provide composition of matter protection for this novel molecule. These patents and allowances underscore the company’s strategy to obtain broad protection for its discoveries and represent an important milestone in the development of this attractive product candidate.”

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs